First-line bevacizumab (BEV) plus chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.

被引：1
|
作者：
Kahan, Zsuzsanna [1 ]
Petruzelka, Lubos [2 ]
Eniu, Alexandru [3 ]
Anghel, Rodica [4 ]
Koynov, Krassimir [5 ]
Vrbanec, Damir [6 ]
Lang, Istvan [7 ]
Ahlers, Silke [8 ]
Brodowicz, Thomas [9 ,10 ]
Zielinski, Christoph [9 ,10 ]
机构：
[1] Univ Szeged, Szeged, Hungary
[2] Charles Univ Prague, Prague, Czech Republic
[3] Inst Canc Res, Cluj Napoca, Romania
[4] Univ Med & Pharm Bucharest, Bucharest, Romania
[5] Univ Hosp, Sofia, Bulgaria
[6] Univ Hosp Rebro, Zagreb, Croatia
[7] Natl Inst Oncol, Budapest, Hungary
[8] IST GmbH, Mannheim, Germany
[9] Med Univ Vienna, Vienna, Austria
[10] CECOG, Vienna, Austria
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB177
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
    Lang, Istvan
    Brodowicz, Thomas
    Ryvo, Larisa
    Kahan, Zsuzsanna
    Greil, Richard
    Beslija, Semir
    Stemmer, Salomon M.
    Kaufman, Bella
    Zvirbule, Zanete
    Steger, Guenther G.
    Melichar, Bohuslav
    Pienkowski, Tadeusz
    Sirbu, Daniela
    Messinger, Diethelm
    Zielinski, Christoph
    LANCET ONCOLOGY, 2013, 14 (02): : 125 - 133
  • [2] Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
    Zielinski, Christoph
    Lang, Istvan
    Inbar, Moshe
    Kahan, Zsuzsanna
    Greil, Richard
    Beslija, Semir
    Stemmer, Salomon M.
    Zvirbule, Zanete
    Steger, Guenther G.
    Melichar, Bohuslav
    Pienkowski, Tadeusz
    Sirbu, Daniela
    Petruzelka, Lubos
    Eniu, Alexandru
    Nisenbaum, Bella
    Dank, Magdalena
    Anghel, Rodica
    Messinger, Diethelm
    Brodowicz, Thomas
    LANCET ONCOLOGY, 2016, 17 (09): : 1230 - 1239
  • [3] An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC)
    Ahlgren, P.
    Thirlwell, M.
    O'Regan, R.
    Mormont, C.
    Levesque, L.
    Gaspo, R.
    Woloj, M.
    Bello, A.
    Martell, B.
    Leyland-Jones, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
    Takashima, Tsutomu
    Mukai, Hirofumi
    Hara, Fumikata
    Matsubara, Nobuaki
    Saito, Tsuyoshi
    Takano, Toshimi
    Park, Youngjin
    Toyama, Tatsuya
    Hozumi, Yasuo
    Tsurutani, Junji
    Imoto, Shigeru
    Watanabe, Takanori
    Sagara, Yoshiaki
    Nishimura, Reiki
    Shimozuma, Kojiro
    Ohashi, Yasuo
    LANCET ONCOLOGY, 2016, 17 (01): : 90 - 98
  • [5] Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
    Hegewisch-Becker, Susanna
    Graeven, Ullrich
    Lerchenmueller, Christian A.
    Killing, Birgitta
    Depenbusch, Reinhard
    Steffens, Claus-Christoph
    Al-Batran, Salah-Eddin
    Lange, Thoralf
    Dietrich, Georg
    Stoehlmacher, Jan
    Tannapfel, Andrea
    Reinacher-Schick, Anke
    Quidde, Julia
    Trarbach, Tanja
    Hinke, Axel
    Schmoll, Hans-Joachim
    Arnold, Dirk
    LANCET ONCOLOGY, 2015, 16 (13): : 1355 - 1369
  • [6] Hormone therapy versus chemotherapy as first-line treatment for estrogen receptor-positive metastatic breast cancer (MBC) patients
    Chang, T. Y.
    Lin, C.
    Lu, Y.
    Kuo, S. H.
    Huang, S.
    Huang, C.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial
    Ryan, P. D.
    Neven, P.
    Blackwell, K. L.
    Dirix, L. Y.
    Barrios, C. H.
    Miller, W. H., Jr.
    Fein, L. E.
    Fenton, D.
    Benner, R. J.
    Meech, S. J.
    Paccagnella, L.
    Sleight, B.
    Yee, D.
    Goss, P. E.
    CANCER RESEARCH, 2011, 71
  • [8] Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
    Koeberle, D.
    Betticher, D. C.
    von Moos, R.
    Dietrich, D.
    Brauchli, P.
    Baertschi, D.
    Matter, K.
    Winterhalder, R.
    Borner, M.
    Anchisi, S.
    Moosmann, P.
    Kollar, A.
    Saletti, P.
    Roth, A.
    Frueh, M.
    Kueng, M.
    Popescu, R. A.
    Schacher, S.
    Hess, V.
    Herrmann, R.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 709 - 714
  • [9] Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT
    Inbar, Moshe J.
    Lang, Istvan
    Kahan, Zsuzsanna
    Greil, Richard
    Beslija, Semir
    Stemmer, Salomon M.
    Kaufman, Bella
    Ahlers, Silke
    Brodowicz, Thomas
    Zielinski, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer
    Wainberg, Zev
    Hecht, J. Randolph
    CLINICAL COLORECTAL CANCER, 2006, 5 (05) : 363 - 367
12345